Abstract
This chapter describes the basic categories for regulatory approval to sell/market a molecular profiling technology. The US Food and Drug Administration regulates and provides guidance, for marketing in vitro diagnostic devices (IVD). Three different paths currently exist for obtaining Food and Drug Administration (FDA) approval of an IVD: (a) If the new test can be shown to be substantially equivalent to an existing predicate test on the market, then the 510(k) is the regulatory path for new device approval. (b) If your new diagnostic technology cannot be considered substantially equivalent to an existing technology, and will be used to make a critical medical decision concerning the diagnosis, treatment, or medical management, then the premarket approval (PMA) is the regulatory path of choice. (c) If no predicate device exists and the test is of low or moderate risk, it may be eligible for a de novo reclassification. If the test is done “in house,” in the designated laboratory only, for a patient sample that is sent to the laboratory from an outside physician’s office or medical facility, then the test can be potentially marketed under “home brew” guidelines (also known as laboratory developed tests) regulated under the Clinical Laboratory Improvement Amendments (CLIA). The Centers for Medicare and Medicaid Services (CMS) assumes primary responsibility for financial management operations of the CLIA program, but the categorization of commercially marketed in vitro diagnostic tests under CLIA is the responsibility of the FDA. Definitions, guidelines, information sources, and instructions for data requirements are outlined for each regulatory pathway.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gibbs, J. N. (2009) Making the most of pre-IDE meetings. Genetic Engineering & Biotechnology News 29, 5.
Gibbs, J. N. (2008) Regulatory pathways for molecular Dx. Genetic Engineering & Biotechnology News 28, 14.
Gibbs, J. N. (2009) Banked-Specimen retrospective studies: A clinical validation shortcut or a lengthy detour? Genetic Engineering & Biotechnology News 29, 12.
van’t Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M. et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–6.
van de Vijver, M. J., He, Y. D., van’t Veer, L. J., Dai, H., Hart, A. A., Voskuil, D. W. et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999–2009.
Knauer, M., Mook, S., Rutgers, E. J., Bender, R. A., Hauptmann, M., van de Vijver, M. J. et al. (2010) The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 120, 655–61.
Gibbs, J. N. (2009) Adroit Crafting of “Intended Use” Critical
Regulatory Fate of a New IVD May Well Depend on a Few Dozen Words. Genetic Engineering & Biotechnology News 28, 20.
Food and Drug Administration, U. S. (2009) Premarket notification (510k).
Food and Drug Administration, U. S. (2009) New Section 513(f)(2) - Evaluation of Automatic Class III Designation, Guidance for Industry and CDRH Staff.
Food and Drug Administration, U. S. (2009) Deciding When to Submit a 510(k) for a Change to an Existing Device (K97-1).
Food and Drug Administration, U. S. (2009) Guidance on the CDRH Premarket Notification Review Program 6/30/86 (K86-3).
Food and Drug Administration, U. S. (2009) 510(k) “Substantial Equivalence” Decision Making Process.
Food and Drug Administration, U. S. (2009) Guidance documents (Medical Devices).
Food and Drug Administration, U. S. (2002) The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry.
Food and Drug Administration, U. S. (2009) Code of Federal Regulations Title 21 21CFR814.
Food and Drug Administration, U. S. (2009) Manual of Compliance Policy Guides.
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J. et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131, 18–43.
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J. et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25, 118–45.
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–82.
Birner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., Hausmaninger, H. et al. (2001) Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7, 1669–75.
Bartlett, J. M., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P. et al. (2001) Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195, 422–8.
Food and Drug Administration, U. S. (2007) Guidance for Industry and FDA Staff commercially distributed analyte specific reagents (ASRs):Frequently Asked Questions.
Department of Health & Human Services, U. S. (2009) Clinical Laboratory Improvement Amendments (CLIA).
Goetz, M. P., Suman, V. J., Ingle, J. N., Nibbe, A. M., Visscher, D. W., Reynolds, C. A. et al. (2006) A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12, 2080–7.
Ma, X. J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A. et al. (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24, 4611–9.
Ma, X. J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V. et al. (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14, 2601–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Liotta, L.A., Petricoin, E.F. (2012). Regulatory Approval Pathways for Molecular Diagnostic Technology. In: Espina, V., Liotta, L. (eds) Molecular Profiling. Methods in Molecular Biology, vol 823. Humana Press. https://doi.org/10.1007/978-1-60327-216-2_27
Download citation
DOI: https://doi.org/10.1007/978-1-60327-216-2_27
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-215-5
Online ISBN: 978-1-60327-216-2
eBook Packages: Springer Protocols